This application is directed to inhibitors of RAD51 represented by the following structural formula,

##STR00001##

and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.

This heat-sensitive recording material is configured to contain, as a color-developing compound, at least one compound represented by one of formulas (1)-(3):

##STR00001##

This heat-sensitive recording material is configured to contain, as a color-developing compound, at least one compound represented by one of formulas (1)-(3):

##STR00001##

Provided herein are methods for identifying compounds that are inhibitors of a calcium-activated chloride channel. Aminothiophene and aminothiazole compounds, and compositions comprising these compounds, described herein that inhibit efflux of chloride through a calcium-activated chloride channel are useful for treating diseases, disorders, and sequelae of diseases, disorders, and conditions that are associated with aberrantly increased chloride and fluid secretion, for example, secretory diarrhea.

Provided herein are methods for identifying compounds that are inhibitors of a calcium-activated chloride channel. Aminothiophene and aminothiazole compounds, and compositions comprising these compounds, described herein that inhibit efflux of chloride through a calcium-activated chloride channel are useful for treating diseases, disorders, and sequelae of diseases, disorders, and conditions that are associated with aberrantly increased chloride and fluid secretion, for example, secretory diarrhea.

The disclosure provides compounds and method useful for modulating gp130 biological activity. The disclosure also provides methods and compositions for treating disease and disorders associated with gp130 activity, particularly those associated with inflammation.

[Problem] The present invention addresses the problem of providing a novel compound. The present invention also addresses the problem of providing an OCT3 detection agent or an OCT3 activity inhibitor, which comprises the novel compound. [Solution] A compound represented by formula (A), a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.
R.sup.1-R.sup.2-R.sup.3-R.sup.4  (A)

[Problem] The present invention addresses the problem of providing a novel compound. The present invention also addresses the problem of providing an OCT3 detection agent or an OCT3 activity inhibitor, which comprises the novel compound. [Solution] A compound represented by formula (A), a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.
R.sup.1-R.sup.2-R.sup.3-R.sup.4  (A)

2-aminothiazole derivatives represented by formula (I), where R.sub.1 and R.sub.2 represent cycloalkyls, respectively; or R.sub.1 represents a substituted aromatic group, and R.sub.2 represents H, a C.sub.1-C.sub.11 alkyl, —CH.sub.2Ph (benzyl), or a methyl ether including a C.sub.1-C.sub.11 alkyl. R.sub.3 is a substituent including an amino group. X represents a carbonyl or a methylene and n is an integer from 0 to 5.

2-aminothiazole derivatives represented by formula (I), where R.sub.1 and R.sub.2 represent cycloalkyls, respectively; or R.sub.1 represents a substituted aromatic group, and R.sub.2 represents H, a C.sub.1-C.sub.11 alkyl, —CH.sub.2Ph (benzyl), or a methyl ether including a C.sub.1-C.sub.11 alkyl. R.sub.3 is a substituent including an amino group. X represents a carbonyl or a methylene and n is an integer from 0 to 5.